Last reviewed · How we verify
Amlodipine-folic acid placebos
Amlodipine-folic acid placebos is a Calcium channel blocker with vitamin supplement Small molecule drug developed by Shenzhen Ausa Pharmed Co.,Ltd. It is currently FDA-approved for Hypertension, Angina pectoris. Also known as: Amlodipine-folic acid (dummy).
Amlodipine blocks L-type calcium channels to reduce blood pressure, while folic acid supplementation supports cardiovascular and metabolic health.
Amlodipine blocks L-type calcium channels to reduce blood pressure, while folic acid supplementation supports cardiovascular and metabolic health. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Amlodipine-folic acid placebos |
|---|---|
| Also known as | Amlodipine-folic acid (dummy) |
| Sponsor | Shenzhen Ausa Pharmed Co.,Ltd |
| Drug class | Calcium channel blocker with vitamin supplement |
| Target | L-type calcium channel (amlodipine); folate metabolism (folic acid) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, causing vasodilation and reduced peripheral vascular resistance. Folic acid (vitamin B9) is included as a supplementary component to support homocysteine metabolism and reduce cardiovascular risk. This combination product targets hypertension management with adjunctive nutritional support.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
Key clinical trials
- China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT) (PHASE4)
- China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine-folic acid placebos CI brief — competitive landscape report
- Amlodipine-folic acid placebos updates RSS · CI watch RSS
- Shenzhen Ausa Pharmed Co.,Ltd portfolio CI
Frequently asked questions about Amlodipine-folic acid placebos
What is Amlodipine-folic acid placebos?
How does Amlodipine-folic acid placebos work?
What is Amlodipine-folic acid placebos used for?
Who makes Amlodipine-folic acid placebos?
Is Amlodipine-folic acid placebos also known as anything else?
What drug class is Amlodipine-folic acid placebos in?
What development phase is Amlodipine-folic acid placebos in?
What are the side effects of Amlodipine-folic acid placebos?
What does Amlodipine-folic acid placebos target?
Related
- Drug class: All Calcium channel blocker with vitamin supplement drugs
- Target: All drugs targeting L-type calcium channel (amlodipine); folate metabolism (folic acid)
- Manufacturer: Shenzhen Ausa Pharmed Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Also known as: Amlodipine-folic acid (dummy)
- Compare: Amlodipine-folic acid placebos vs similar drugs
- Pricing: Amlodipine-folic acid placebos cost, discount & access